The pharmaceutical industry is pushing back against Governor Cuomo's prescription drug price control proposal, arguing that it would lead to cuts in research. And they are pointing the finger at insurance companies and companies known as pharmacy benefit managers for the high costs paid by patients. Peter Pitts is a former FDA Associate Commissioner for External Relations and is now President of the Center for Medicine in the Public Interest.
Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal
RECENT NEWS
PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD
How proactive FDA policies can help strengthen the American pharmaceutical supply chain of essential medicines, create jo... Read more
The Empty Price Tag
Why Hospital Price Transparency Has Fallen Short & How Congress Can Make It Right... Read more
We Can Fight Fraud Without Threatening Access to Care
When Washington fails to police its own programs, it’s hardworking Americans that pay the price. ... Read more